Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBI-1501 for Relapsed or Refractory CD19+ B-ALL
NCT03155191Phase 2Active, not recruiting
- Sponsor
- Takara Bio Inc.
- Start
- Jun 2017
- Primary completion
- Mar 2035
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of NIB-101 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Takara Bio Inc.. Started Jun 2017; status: active, not recruiting.
02
Drugs
NIB-101
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03155191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03155191.